In this retrospective cohort, seventy-seven NSCLC patients with CNS metastases who had previously received targeted treatment with EGFR- or ALK-, or ROS1-tyrosine kinase inhibitors (TKIs) were tested for NGS using CSF samples. Here, ROS1 is linked to non-small cell lung carcinoma.